A phase III pivotal study to evaluate the Trabodenoson monotherapy in patients with ocular hypertension or open angle glaucoma
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Trabodenoson (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Inotek Pharmaceuticals
- 31 Mar 2015 Inotek Pharmaceuticals expects to begin this trial in early 2017. If the primary objectives of phase III program are met, then Inotek Pharmaceuticals will submit a NDA to the US FDA for marketing approval of Trabodenoson for glaucoma in the USA and then submit a MAA in Europe subsequently, according to the company SEC filing report 10-K 2014.
- 31 Mar 2015 New trial record created.